Exscientia raises $100m Series C funding to develop fully autonomous drug design
Exscientia has raised $100m in its second Series C in the past nine months. The round was led by BlackRock,…
By
Exscientia has raised $100m in its second Series C in the past nine months. The round was led by BlackRock,…
ByImcyse has raised €21.3m in a Series B round, which includes an equity purchase by new partner Pfizer. The Belgian…
ByNew and existing investors have supported TCR therapy-focused TScan with $100m in an oversubscribed Series C round. The money will…
ByImmuneering has raised $62m in an oversubscribed Series B round led by high-profile life science investors. The money will be…
ByRare neurological disease-focused Noema has raised CHF54m ($60.8m) in a Series A round. The company plans to use the funding…
ByDespite the Covid-19 pandemic, Novo Ventures, the venture capital arm of the Novo Nordisk Foundation's Novo Holdings, has made 18…
ByCelleron spin-out SynOx has closed a €37m Series A funding round led by HealthCap and Medicxi. The funding will be…
ByAraris has closed a CHF15.2m seed round to support the advancement of its pipeline of ADC drugs for unmet needs…
ByThank you for subscribing to Pharmaceutical Technology